This study compared the molecular lipidomic profile of LDL in patients with non-diabetic advanced renal disease and no evidence of cardiovascular disease to that of age-matched controls, with the hypothesis that it would reveal proatherogenic lipid alterations. LDL was isolated from 10 normocholesterolemic patients with stages 4/5 renal disease and 10 controls, and lipids were analysed by accurate mass liquid chromatography-mass spectrometry. Top-down lipidomics analysis and manual examination of the data identified 352 lipid species, and automated comparative analysis demonstrated alterations in lipid profile in disease. The total lipid and cholesterol content was unchanged, but levels of triacylglycerides and N-acyltaurines were significantly increased, while phosphatidylcholines, plasmenyl ethanolamines, sulfatides, ceramides and cholesterol sulfate were significantly decreased in CKD patients. Chemometric analysis of individual lipid species showed very good discrimination of control and disease sample despite the small cohorts, and identified individual unsaturated phospholipids and triglycerides mainly responsible for the discrimination. These findings illustrate the point that although the clinical biochemistry parameters may not appear abnormal, there may be important underlying lipidomic changes that contribute to disease pathology. The lipidomic profile of CKD LDL offers potential for new biomarkers and novel insights into lipid metabolism and cardiovascular risk in this disease.
Introduction
Chronic kidney disease (CKD) is a serious and increasingly common condition (1) .
Patients with CKD have a greatly increased risk of cardiovascular disease (CVD), which represents the most common cause of mortality and morbidity in these patients, to the extent that CKD is considered an independent risk factor for CVD (2, 3) . In CKD, many conventional risk factors for CVD are prevalent, including hypertension, dyslipidemia and insulin resistance.
Underlying conditions that are typical of CVD also occur, such as heightened inflammatory status, oxidative stress, endothelial dysfunction and arterial stiffness (3, 4) . Consequently, understanding the factors in CKD that could contribute to increased CVD risk is very important.
In CVD there is a clearly established link between dyslipidemia (specifically hypercholesterolemia and hypertriglyceridemia) and atherosclerosis, an underlying pathology of most CVD (5, 6) . In view of the clear cardio-renal relationship, there has been considerable interest in the possible contribution of hyperlipidemia to CKD-associated CVD (7, 8) . The nature of this lipid imbalance is significantly different to non-renal-related CVD; in particular, the relationship with cholesterol level is less clear than in the general population and is dependent on the stage of disease (9, 10) . In some patients, total cholesterol and LDL-cholesterol are not elevated, while patients on hemodialysis may even have reduced cholesterol compared to control subjects (11) . It is apparent that CKD involves multiple lipid abnormalities, some of which may contribute to increased CVD risk. However, most studies of lipid abnormalities in CKD have focused on lipoprotein profile or on overall lipid classes such as triglycerides. Whilst in many inflammatory diseases, including pre-eclampsia (12) , diabetes (13) , rheumatoid arthritis (14) and Crohn's disease (15) , lipidomic studies have identified characteristic lipid signatures that have potential as diagnostic tools, there have as yet been few attempts at profiling individual lipids in CKD. Evidence for an altered phospholipid profile in CKD (16) and a decrease of serum sulfatide levels in patients with end-stage renal failure (17) have been reported, but otherwise little is known about molecular changes. 4 Modern lipidomics depends almost entirely on analysis by electrospray mass spectrometry, as this is able to identify a very wide variety of individual lipid species in several classes. Both shotgun lipidomics, involving direct infusion of the sample into the instrument, and liquid chromatography coupled to mass spectrometry (LC-MS) are widely used for this purpose (18) . Chromatographic separation provides additional information to facilitate lipid identification, and separation of the lipids reduces interference (19). Although with lower resolution instruments, tandem MS is necessary to distinguish lipids of similar mass but different formula, modern high resolution instruments such as orbitraps offer sufficient mass accuracy that isobaric species can be distinguished, thus allowing classification of lipid analytes and identification of the total number of carbons and double bonds in the acyl chains by a top-down approach (20) . It has been demonstrated that this untargetted approach, coupled with principle component analysis, can be used without internal standards for comparative analysis of lipidomes, owing to the high dynamic range of the orbitrap (21). Similar "semi-quantitative" approaches on a triple quadrupole instrument have also been used for comparative lipidomics in cardiovascular disease (22, 23). However, tandem MS or MS n is still required for confirmation of individual acyl chain length and double bonds.
We recently demonstrated that a top-down lipidomics approach using liquid chromatography interfaced to mass spectrometry on a high resolution instrument (Orbitrap Exactive) was able to identify more than 350 individual lipid species or isomeric lipid clusters in normo-lipidemic LDL (24). The lipids were identified by matching the experimental m/z for the molecular ions to calculated mono-isotopic masses available in lipidomic and metabolic databases. LDL is an important carrier of a wide variety of lipid species within the plasma, and reflects systemic changes in lipid metabolism. We hypothesized that the application of this methodology to CKD would identify novel differences in lipid profile at a molecular level between disease and control samples that would enhance understanding of the disease mechanisms and offer potential as diagnostic markers.
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Plasma samples and LDL separation LDL was isolated from plasma aliquots essentially as described previously (26). KBr (0.3816 mg) was dissolved in 1 mL of plasma at 4 o C, and underlaid below 4.1 ml of a deoxygenated EDTA solution, before centrifuging in a Beckman VTi 90 rotor for 2 hours at 60,000 rpm to generate a density gradient. LDL formed bands in the density range 1.019-1.060 g/mL. The LDL collected was stored in sterile vials under nitrogen, and desalted before determining the cholesterol content using CHOL PAD reagent (Roche Diagnostics) and protein concentration of isolated LDL was determined by the Bradford assay as reported by Yue et al.
(27). Purity of isolated LDL was confirmed by polyacrylamide gel electrophoresis (24, 28).
Vitamin E content
Vitamin E content (α-tocopherol) in LDL was determined by reverse-phase chromatography using spectrophotometric detection as described previously (29). The samples and standards were injected randomly in triplicate and area under the curve (AUC) was plotted against the calibration curves and used to calculate the concentration of vitamin E in the samples (µg/mg protein). Standards (0.1-10 µg/mL), made up in methanol and extracts redissolved in 100 µL methanol, were analysed in triplicate by injection of 20µL. The intraday CV (n=3) at a concentration of 2.5 μg/mL was 3.1%. Statistical analysis was carried out using an unpaired t test, with Welch's correction to estimate the p values.
Electrophoretic mobility of LDL
The particle size of LDL was assessed by 1% agarose gel electrophoresis in barbital buffer as described previously (30). Retardation factors (Rf) were defined as the distance (cm)
travelled by sample / distance (cm) travelled by dye front.
Lipid Extraction
LDL lipids were extracted from LDL containing 25 μg protein by the Folch method as described recently (24 C, sheath gas flow: 50 AU, aux gas flow: 17 AU, sweep gas flow: 0 AU. All LC-MS spectra were recorded in the m/z range 100-1200 at 50,000 resolution (FWHM at m/z =500). Three microscans were collected per data point with the injection time limited by either an automatic gain control target ion intensity of 10 6 or a maximum inject time of 250 ms.
8 best detection of the parent ion. The capillary voltage was set at 4.5kV, capillary temperature at 275°C, with sheath gas and sweep gas flow rates set at 30 and 10 AU respectively. Collision energy was set according to the ion of interest, typically between 25-35 (arbitrary units).
LC-MS data processing
In the first stage, LC-MS data were analysed and lipid species identified by manual matching of retention times and accurate mass data to a home-built database and the Human Metabolome project database (HMDB) (31), with identifications based on ions showing a mass error of <5 ppm (and in most cases <2 ppm) to the mono-isotopic mass calculated from the theoretical formula. 352 lipids were identified by this approach.
Subsequently, LC-MS data were analysed by filtering with MZMatch (32) followed by using the XCMS pipeline (XCMS Online version 0.0.83, Scripps Center for Metabolomics, https://xcmsonline.scripps.edu/, (33)) for peak detection, alignment and isotope annotation as described previously (24). Ions with intensity <5000 cps were excluded. Integration of features extracted in different samples corresponds to the reported extracted ion chromatogram areas.
Peak intensities for the ions identified from individual lipid classes in the datasets were summed and used to evaluate overall differences in disease vs. age-matched control groups. Extracted features were included if they were present in >50% of the samples in each group, were within 2.5 ppm from the exact mono-isotopic mass, and with < 5s retention time deviation. In order to prevent overestimation of the number of lipid species identified, all lipid species detected in positive and negative ion modes were manually cross-referenced. Overall, 142 and 158 individual lipids were identified in positive and negative ion modes, respectively. Isomeric 9
Statistical analysis
The merged data set comprising 300 lipids species (Supplementary Figure 1) , were further analysed using Partial Least Squares Discriminant Analysis (PLSDA) (34, 35). PLSDA calibration models were validated using segmented cross-validation, and optimization of PLSDA models was achieved using the Variable Importance in Projection (VIP) score (36). A VIP cutoff value of 0.8 was repeatedly applied to eliminate less discriminating variables, with a cut-off of 0.85 for the merged set. The final classification model included 48 species detected in the positive mode and 55 in the negative mode. The statistical significance of the classification PLSDA models was assessed using permutation testing with 1000 permutations (37). Q 2 was used as quality-of-fit criterion for the permutation test (38). Further details are given in Supplemental methods.
Statistical analysis of clinical and biochemical parameters was conducted using nonparametric t-tests (Mann-Whitney) using two-tailed p value calculation, and values with p<0.05
were considered statistically significant.
10

RESULTS
Evaluation of clinical and biochemical parameters in kidney disease
Baseline measurements of clinical and biochemical parameters for age-and body massmatched subjects included in this study are summarized in Table 1 . Glomerular filtration rate (GFR) was estimated using the MDRD equation and confirmed all patients as stage 4 or 5 CKD;
they also had significantly increased systolic BP. There were no significant differences in levels of glycated hemoglobin and plasma glucose. The inflammatory marker C-reactive protein was significantly elevated, although IL-6 was not. The levels of total plasma cholesterol and LDL
were not altered with CKD and there was no change in OxLDL. In contrast, HDL levels showed a significant decrease and plasma triglycerides were elevated, as expected for patients with CKD and published previously (25). LDL vitamin E content and particle heterogeneity (electrophoretic mobility) were also determined but there was no statistical difference ( Table 1) . ions with intensity <5000 cps, the requirement that peaks were present in >50% of samples in either group, and the ability of the programme to adjust for minor differences in retention times.
Analysis of LDL
The intensities of ions identified in this dataset were summed to provide an estimate of the total lipid intensity and the lipid intensity in each of the identified classes, following a previously published procedure (24). The variability of total lipids extracted (extraction repeatability and analytical reproducibility) between replicates in the samples of control and disease group was <10%, thus enabling this approach to be used for comparisons of lipid content 12 between samples for any one lipid class, although it cannot be used for comparisons between lipid classes owing to differences in ionization efficiencies.
The total lipid in LDL remained essentially unaltered in the CKD patient group compared to the age-matched control group (Figure 2a ), but changes in the intensity of a number of lipid classes were observed in LDL. There was an observed statistically significant increase in triacylglycerides (Figure 2b ), in agreement with the clinical data in Table 1 , whereas the content of phosphatidylcholines decreased significantly in the CKD group (Figure 2c ). There were no changes in the intensities of total cholesterol and sphingomyelins, or in the total levels of phosphatidylethanolamines (PE) (data not shown), although the contribution of PE containing a vinyl ether linkage to the total PE pool was significantly lower in CKD samples ( Figure 2d ).
Interestingly, the total content of lyso-lipids (LPC+LPE) in LDL in disease patients was similar when compared to age-matched controls (Figure 2e ), but the ratio of lyso-lipid types (LPC/LPE)
showed a significant decrease in LDL from CKD samples (Figure 2f ). In addition, changes in CKD were observed in 4 other lipid class that constitute minor components of LDL; specifically, the content of ceramides (Figure 3a For a full statistical analysis of the MS data and to identify the contribution of individual lipid species to differences between the control and CKD samples, Partial Least Squares Discriminant Analysis (PLSDA) was used. The classification summary for three optimized models calculated using lipid profiles measured in positive and negative ion modes and the 13 merged (+ve plus -ve mode) data set, are shown in Table 3 between 0.96 and 1 for the cross-validation data, though slightly better results were obtained using merged data (Table 3 ). The closer the values are to 1 the better the quality of the model.
The ions that contributed most strongly to the discrimination can be determined from their contribution to the PLSDA model, and were unsaturated lipid species from the most abundant lipid classes, namely PC, TAG and PE; the complete set of discriminating ions is indicated in Supplemental Table 2 However, minor lipid subclasses also showed significant differences in CKD and control LDL, specifically cholesterol sulphate, sulfatides, and ceramides, which were lower in CKD LDL, and N-acyltaurines, which increased in CKD LDL, compared to control. Thus although the clinical lipoprotein profile only showed an increase in triglycerides and a decrease in HDL, detailed molecular analysis identified several lipid classes and subclasses that are altered in LDL, and within these classes, changes in several molecular lipid species.
Some of the molecular changes observed in the LDL lipidome in CKD are linked to atherogenic mechanisms, and therefore could explain the increased risk of CVD in these patients.
PCs are phospholipids present in the surface monolayer of LDL, and are important for the conformation of ApoB-100, macrostructure of LDL, and its correct interaction with LDL receptors (41, 42). Interestingly, the overall decreased PC observed in this study was apparently not sufficient to cause major structural changes in the LDL, as there was no significant change in (17) reported that sulfatides were the only factor that discriminated control from ESRF groups in their study, and that they have promise as biomarkers for CKD. We observed a decrease in the level of ceramides in LDL from CKD patients; however, as increased sphingomyelinase activity and free ceramides are thought to be linked to atherogenesis (48, 49), this does not appear to contribute to the pro-atherogenic profile of CKD. Finally, it was also noted that there was a significant increase in taurine-containing lipoamino acids (LAA) in LDL from CKD patients. LAAs are well known as components of mammalian nervous tissue and are involved in signaling neuronal events (50), and have only recently been detected in LDL (24). In neuronal ischemia these lipids have been reported to show protective and anti-inflammatory effects (51), but they can also induce apoptosis of macrophages (52). As yet, their role in lipoproteins and potential atherogenic contribution has not been elucidated.
A limitation of this study is that only patients with severe kidney disease and agematched controls were compared, so, in the absence of intermediate stages, limited conclusions about the role of these changes in disease progression can be drawn. Also, the CKD patients studied here had minimal comorbidity with no current clinically apparent CVD, despite the high risk of developing CVD. Although in this cohort the levels of hsCRP were high, indicating some 16 inflammation, IL-6 and measures of oxidative stress (OxLDL) were low. These findings differ from some previous studies (3, 4) where both inflammation and oxidative stress were substantially increased in CKD and contribute significantly to its accelerated vascular pathology.
Our data suggest that uremia is not itself pro-oxidant and this feature may be driven largely by co-morbidity. However, it is unclear whether uremia or increased inflammation are responsible for the LDL lipidomic changes, or result from them. These changes in CKD patients are unlikely to be the consequence of lipid lowering drugs, as only 2 patients were on statin therapy and none A limitation of the top-down lipidomic methodology is that some features in the mass spectra remain unidentified and it is not possible to discriminate some individual lipids within isomeric clusters, so further differences could be present that are not reported here. It should be noted that as internal standards were not used, the analysis is comparative and semi-quantitative. triacylglycerides; c) total phosphatidylcholine; d) ratio of plasmenyl ethanolamine to total phosphatidyl-ethanolamine; e) total lyso-phosphatidylcholine and lysophosphatidylethanolamine; f) ratio of lyso-phosphatidylcholine to lysophosphatidylethanolamine. Box plots showing changes in major lipids in the disease group (n=10) against the agematched control group (n=10). Samples were analysed in triplicate (n=3) and statistical analysis was carried out using the Mann-Whitney test to estimate the P values. Differences were considered statistically significant at p<0.05. Plots are a) total lipids detected; b) triacylglycerides; c) total phosphatidylcholine; d) ratio of plasmenyl ethanolamine to total phosphatidyl-ethanolamine; e) total lyso-phosphatidylcholine and lyso-phosphatidylethanolamine; f) ratio of lysophosphatidylcholine to lyso-phosphatidylethanolamine. 
Supplemental Information
PLSDA Statistical analysis
PLSDA is one of the most commonly used classification methods for analysis of omics data, especially metabolomics. It is based on the Partial Least Square regression (PLS) approach and consists of using standard PLS algorithm with dummy dependent y variables containing class labels.
As our data is a two-class case, control and disease, the values of the dependent variable were given as 1 for one class and -1 for the other class. PLSDA can be prone to overfit data, and so rigorous validation was undertaken. Optimization and validation of the PLSDA classification model and assessment of model quality were carried out using a cross validation and permutation test, using Q 2 as a measure of quality of the model. Cross-validation ensured that optimization and validation remained independent of each other. The statistical significance of the PLSDA classification model was assessed using a permutation test (1, 2) . Permutation testing consists in changing randomly the order of the rows in the data set so the class labels are assigned randomly to the measurements. The classification model is then recalculated using this permuted data set. Permutation test considers the null hypothesis that a given classification model is not significant and describes noise. If null hypothesis is true, there should be no difference in the value of the quality-of-fit criteria between original data set and permuted one. After permuting the data and repeating calculations a sufficient number of times a null hypothesis (H0) distribution of the quality-of-fit criterion is obtained. For the results to be considered significant, the value of the quality-of-fit criterion for the original, nonpermuted data set should be outside either the 95 or 99% confidence bounds of the H0 distribution of the values generated from the permuted data.
In the present study data were permuted 1000 times and Q 2 was used as quality-of-fit criterion for the permutation test. Q 2 is based on an evaluation of the error between the predicted and known variables, and was calculated using the following formula (38):
where y i is a value for the i th sample, � is a predicted value for the i th sample and � is the mean y value.
Selection of the lipid species contributing to the discrimination between CKD patient and control groups was achieved using the Variable Importance in Projection (VIP) (36), which is effectively the weighted sum of the squares of the weight in the PLS analysis, and allows ranking of the variables according to their importance in the PLS model.VIP takes into account amount of the variance explained by the variable for each latent variables extracted and covariance between this variable and dependent variable y.
VIP of the j th variable, VIP j , for the model with K latent variables is calculated using the following equation:
, where p is a total number of variables in the model, t k and b k are scores and regression coefficient for the k th latent variable, respectively, and w jk is a weight for the j th variable and k th latent variable.
A VIP cut-off value of 0.85 was used for the merged set. The final classification model included 48 species detected in the positive mode and 55 in the negative mode.
PLSDA, permutation test and VIP algorithms were implemented in MATLAB, v. 7.12 (release 2011a). 
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Supplemental Table 1 . List of ions observed in the averaged mass spectra (LC-MS) for each of the different lipid classes composing LDL population detected with polarity switching. The corresponding molecular formulae and proposed identifications of the lipid species are given, based on a mass error of <5 ppm between the experimental accurate mass and the calculated monoisotopic mass from the theoretical formula obtained using a home-built database and the Human Metabolome Project (HMDB).
The m/z values used in this analysis were manual peak-top measurements, and may differ fractionally from the values quoted in Supplemental Table 2 , which are mean m/z values from the automated extraction of features detected in at least 50% of data files, with error <2.5ppm and with 5s of retention time deviation. "d" indicates diacyl phospholipids and "p" indicates plasmanyl / plasmenyl phospholipids. The structures (C:n) are proposed based on the total number of carbons that compose the fatty acyl chains and the total number of double bonds that may be considered for the m/z value observed.
Lipid sub-classes
* Plasmalogen phospholipid species may contain the contribution of alkyl-or alkenyl-acyl. ** Compounds may contain the contribution of sphin-4-enine or sphinganine structure. Table 2 . Identification of lipid species that were found to be discriminating for CKD using PLSDA. A final cut-off of 0.85 for the significance factor was used. Rt med and m/z med correspond to the averaged retention time and mass-to-charge ratio of an identified feature from all chromatographic runs in which the feature was identified. The lipid species were identified by matching the experimental m/z to the calculated monoisotopic mass to within 5 ppm mass accuracy. The m/z values quoted in this table are mean m/z values from the automated extraction of features, and hence may differ fractionally from the manual peak-top m/z values quoted in Supplemental 
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